LONGEVA.

Semax: limits of adverse-reaction evidence

Filippenkov and colleagues studied ACTH(4–7)PGP (Semax) in a rat cerebral-ischaemia model. The 2020 abstract describes gene expression 24 hours after ischaemia modelling. [1]

This abstract gives no clinical adverse-reaction frequencies. Administration route has not been verified from it; these data cannot establish human or batch-specific safety for Semax. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Clinical adverse-reaction frequenciesRat cerebral-ischaemia model; gene expression 24 hours after ischaemia modellingThe abstract gives no clinical adverse-reaction frequencies; these data cannot establish human safety for Semax[1]

References

  1. Filippenkov IB et al. (2020). Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats https://doi.org/10.3390/genes11060681.